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Abstract
Cells infected with dengue virus release a high proportion of immature prM-containing virions. In accordance, substantial
levels of prM antibodies are found in sera of infected humans. Furthermore, it has been recently described that the rates of
prM antibody responses are significantly higher in patients with secondary infection compared to those with primary
infection. This suggests that immature dengue virus may play a role in disease pathogenesis. Interestingly, however,
numerous functional studies have revealed that immature particles lack the ability to infect cells. In this report, we show
that fully immature dengue particles become highly infectious upon interaction with prM antibodies. We demonstrate that
prM antibodies facilitate efficient binding and cell entry of immature particles into Fc-receptor-expressing cells. In addition,
enzymatic activity of furin is critical to render the internalized immature virus infectious. Together, these data suggest that
during a secondary infection or primary infection of infants born to dengue-immune mothers, immature particles have the
potential to be highly infectious and hence may contribute to the development of severe disease.
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Introduction
Dengue virus (DENV) represents a major emerging arthropod-
borne pathogen. There are four distinct serotypes of DENV which,
according to WHO estimates, infect about 50-100 million
individuals annually, mostly in the (sub)tropical regions of the
world. While most DENV infections are asymptomatic or result in
self-limited dengue fever (DF), an increasing number of patients
present more severe, potentially fatal clinical manifestations, such as
dengue hemorrhagic fever (DHF) and dengue shock syndrome
(DSS). It is well established that a major risk factor for the
developmentof DHF/DSS issecondary infectionwitha heterotypic
virus serotype [1–3]. Also primary infection of infants born to
dengue-immune mothers may lead to severe disease [1,4,5]. These
observations have led to the hypothesis of antibody-dependent
enhancement (ADE) of infection [3,6,7]. Increased disease severity
appears to correlate with high circulating virus titers [3,8–11],
suggesting that antibodies directly influencetheinfectiousproperties
of the virus. The molecular mechanisms by which antibodies
enhance DENV infection however remain elusive.
DENV, as well as other major human pathogens like West Nile
virus (WNV), yellow fever virus, and tick-borne encephalitis
(TBEV) belong to the Flavivirus genus within the family
Flaviviridae. Flaviviruses enter cells via clathrin-mediated endocy-
tosis and fuse from within acidic endosomes, through which the
viral genome gains access to the target cell cytoplasm[12].
Following RNA replication and protein translation, immature
virions, which contain heterodimers of the transmembrane
proteins E and a precursor form of M (prM), are assembled
within the ER. Subsequently, the particles mature by passing
through the Golgi and trans-Golgi network (TGN) [13]. In the
acidic environment of the TGN, the virion undergoes a
conformational change and the cellular endoprotease furin cleaves
prM into M and a peptide (‘‘pr’’) that remains associated with the
virion [14]. Upon release, the pr peptide dissociates from the
virion, resulting in the formation of mature progeny virions.
Cells infected with DENV secrete high levels (,30%) of prM-
containing immature particles [15,16] suggesting that cleavage of
prM to M is not efficient. These DENV particles are released from
infected cells as fully immature prM-containing particles and
partially immature particles containing both prM and M proteins
in the viral membrane [17]. Extensive functional analyses have
revealed that fully immature flaviviruses lack the ability to infect
cells, as the presence of uncleaved prM in the virion blocks the E
glycoprotein from undergoing the pH-induced conformational
changes that are required for membrane fusion [16,18–22].
Although immature particles are therefore generally considered as
irrelevant by-products of infected cells, the rates of prM antibody
responses are significantly higher in patients with secondary
infection compared to those with primary infection [23].
Furthermore, previous reports show that prM antibodies can
enhance DENV infection. Enhancement of infection was observed
for wild-type virus [24,25], presumably due to the presence of
uncleaved prM in these preparations, and with DENV particles
containing high levels of prM generated from cells treated with
chloroquine [26]. It is thus quite puzzling if indeed the presence of
prM obstructs DENV infectivity, how immature particles
contribute to disease pathogenesis and what role do anti-prM
antibodies play in the enhancement of infection? The present
study addresses these questions.
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Fully immature dengue virus particles becomes highly
infectious in the presence of prM antibodies
First, we investigated if prM antibodies are able to render fully
immature DENV infectious. To this end, immature DENV-2
strain 16681 particles were produced in furin-deficient LoVo cells.
We have used this procedure before and showed that LoVo-
derived particles have an average content of 94%69% prM [16].
Furthermore, we demonstrated that the specific infectivity of
LoVo-derived fully immature DENV is at least 10,000-fold
reduced compared to that of wild-type virus on cells highly
permissive to infection [16]. The infectious properties of fully
immature DENV virions were determined in Fc-receptor-
expressing K562 cells in the absence or presence of increasing
concentrations of the 70–21 antibody. This is an IgG2a antibody
that has been isolated from DENV-infected mice and is mapped to
amino acids 53-67 of prM [25]. Antibodies recognizing this
epitope are abundantly present in sera of DHF/DSS patients
[16,27]. K562 cells were infected with DENV at a multiplicity of
100 genome-containing particles per cell (MOG 100). The
number of genome-containing particles (GCP) was determined
by quantitative PCR analysis of reverse-transcribed viral RNA
[15]. At 24–48 hours post-infection (hpi), cells were fixed and
prepared for flow-cytometric analysis to determine the number of
infected cells, measured on the basis of dengue E protein
expression. We observed that 43 hpi is optimal for read-out as it
represents a single round of infection together with a high mean
fluorescence intensity per infected cell (Fig. S1).
In agreement with our previous study [15,16], we observed that
fully immature DENV particles are essentially non-infectious as the
number of E-positive cells did not exceed the limit of detection
(Fig. 1A). Remarkably however, substantial numbers of E-positive
cells were observed upon infection of cells with fully immature
particlesopsonizedwiththeanti-prMantibody(Fig.1A).Subsequent
titration of the cell supernatants at 43 hpi revealed that opsonization
of immature DENV with anti-prM antibody dramatically enhanced
(up to 30,000-fold) virus particle production (Fig. 1B). The results
showthatprMantibodiesrenderessentiallynon-infectiousimmature
DENVnearlyasinfectiousaswild-typevirus(Fig.1B).Enhancement
of immature DENV infectivity was seen in a broad antibody
concentration range, even at conditions of high antibody excess.
To ensure that the observed high level of enhancement is not
restricted to a single antibody we performed additional experi-
ments with the murine IgG2a prM antibody 2H2 [28]. The results
show that 2H2 stimulated the infectious properties of fully
immature particles up to 1,000 fold (Fig. S2A). Although, this
antibody has previously been shown to enhance DENV infectivity
[26], the power of enhancement observed here is striking and
demonstrates that prM antibodies render essentially non-infectious
fully immature DENV highly infectious.
Subsequently, we investigated the enhancing properties of both
prM antibodies in Fc-receptor-bearing human monocytic U937
cells and observed that the antibodies again significantly stimulate
the infectivity of immature particles (Fig. 1C, S2B). Thereafter, we
studied the infectious properties of immature DENV particles in
primary human PBMCs, cells which are known to be involved in
dengue pathogenesis. The results show that, also under these
conditions, prM antibodies render fully immature particles
infectious (Fig. 1D, S2C).
Antibodies against prM facilitate binding of immature
dengue virus particles to FccII-receptors on target cells
To better understand the mechanism by which prM antibodies
triggerinfectivityofimmatureDENV,weanalyzed the distinctsteps
in the cell entry pathway of the virus. First, the binding of immature
virions to K562 cells was determined by quantitative-PCR. In order
to determine the number of bound GCP per cell, the amount of
virus added per cell was increased 10-fold compared to the
concentration used in the infectivity experiments. The results show
that antibody-opsonized immature DENV binds approximately 30-
fold more efficiently to cells than immature particles in the absence
of antibody (Fig. 2A). Indeed, immature particles opsonized with
anti-prM bound almost as efficiently to cells as wild-type DENV in
the absence of antibody. Moreover, immature DENV particles
failed to interact efficiently with baby hamster kidney cells (BHK-
15), cells which are highly permissive for dengue infection (data not
shown) suggesting that the observed lack of infectivity is partially
related to the poor binding efficiency of immature particles to cells.
It is likely that binding of virus-antibody complexes is mediated by
direct interaction of the antibody with the Fc-receptor expressed on
the cell surface. Indeed, treatment of cells with an anti-CD32
antibody to block FccII-receptor interaction, or opsonization of
particles with mAb70-21 F(ab’)2 fragments severely reduced virus
particle production upon infection of K562 cells with opsonized
immature virions, whereas it had no effect on infection with wild-
type virus (Fig. 2B). Although this antibody has been previously
described to enhance the infectious properties of wild-type DENV
in cells with or without Fc-receptors [25,27], clearly in the case of
immature particles interaction with the Fc-receptor is important for
infectivity. Taken together, these data indicate that prM antibodies
facilitate efficient interaction and cell entry of virus-immune
complexes via the FccII-receptor.
Furin activity is critical in rendering immature particles
infectious
Efficient FccIIR-mediated cell entry does not however clarify what
is the trigger for immature virions to become infectious, since the
Author Summary
Dengue virus represents a major emerging arboviral
pathogen circulating in the (sub)tropical regions of the
world, putting 2.5 billion people at risk of infection. Each of
the four circulating serotypes can cause disease ranging
from febrile illness to devastating manifestations including
dengue hemorrhagic fever and dengue shock syndrome.
Severe illness is observed in individuals experiencing a re-
infection with a heterologous dengue virus serotype and in
infants born to dengue-immune mothers, presumably due
to antibody-dependent enhancement of infection. Interest-
ingly, it has been recently reported that patients experienc-
ing a secondary infection have elevated levels of antibodies
directed against the prM protein of immature dengue virus
particles. Although it is known that cells infected with
dengue virus release substantial amounts of prM-containing
virions, numerous functional studies have demonstrated
that immature particles lack the ability to infect cells. Herein,
we show that essentially non-infectious fully immature
dengue virions become virtually as infectious as wild type
virus particles in the presence of prM antibodies. Anti-prM
antibodies facilitate efficient binding and entry of immature
dengue virus into cells carrying Fc-receptors. Furthermore,
furin activity in target cells is critical for triggering infectivity
of immature virus. These data indicate that immature
dengue virus has the potential to be highly infectious and
hence may contribute to disease pathogenesis.
prM Antibodies Render Immature DENV Infectious
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of the virus [14,16,18]. One could speculate that anti-prM antibody
bound to immature virions induces a conformational change that
would enable the E protein to trigger membrane fusion irrespective of
the presence of prM. Another scenario might be that prM-containing
virions mature upon cell entry since furin, although predominantly
present in the TGN, also shuttles between early endosomes and the
cell surface. To verify the potential involvement of furin during
virus cell entry, we investigated the infectious properties of
antibody-opsonized immature DENV in cells treated with furin
inhibitor, decanoyl-L-arginyl-L-valyl-L-lysyl-L-arginyl-chloromethylk-
etone (decRRVKR-CMK). In aqueous solution, decRRVKR-CMK
has a half-life of 4–8 h [29] and therefore it is not expected to interfere
with the maturation process of newly assembled virions within the
infected cell. The results show that inhibition of furin activity
completely abrogated virus particle production in cells infected with
antibody-opsonized immature virions, whereas infection of cells with
wild-type virus remained unaffected under these conditions (Fig. 3A).
To further substantiate the role of furin in triggering viral infectivity,
we generated a furin cleavage-deficient virus (pDENprMD90) by
deletion of the lysine on the position 90 (87-R-R-E-K-R-91) within the
furin recognition sequence. Subsequently, DENVprMD90 virus and
wild-type DENV-2 16681 (generated from pD2/IC-30P) virus were
produced by transfection of RNA transcripts derived from the cDNA
plasmids into BHK-15 cells. Virus production was measured by
determining the number of physical particles based on GCP and the
number of infectious units as measured by plaque assay. The presence
of physical particles was further evaluated in three-layer ELISA
experiments, by coating plates with a similar number of genome-
containing DENVprMD90 particles and LoVo-derived immature
particles. Similar OD values were measured for DENVprMD90 and
LoVo-derived viruses (data not shown), which confirms the presence
of physical particles and suggests that the number of genome-
containing particles is accurately determined. Subsequent titration
studies revealed that the specific infectivity of DENVprMD90 mutant
virus is reduced by a factor of 12.000 compared to that of wild-type
virus (generated from pD2/IC-30P) and is comparable to LoVo-
derived immature virus. Next, K562 cells were infected with
DENVprMD90 mutant virus opsonized with increasing concentra-
tions of prM antibody 70–21. Figure 3B shows that disruption of the
furin-recognition motif within the prM protein of the virus abrogates
the enhancing activity of the anti-prM-antibody, demonstrating that
enzymaticcleavage ofprMtoM byfurin is critical torenderimmature
DENV infectious.
Figure 1. Immature DENV particles become highly infectious in the presence of anti-prM antibodies. K562 cells were infected with
immature (prM) or wild-type (wt) DENV-2 strain 16681 at MOG 100 in the presence or absence of anti-prM 70–21. (A) Representative read-out of the
percentage of infected cells. Prior to infection, immature DENV particles were incubated with 40 ng/ml 70–21 antibody for 1 h at room temperature.
At 43 hpi, the cells were fixed, stained intracellularly with Alexa-647-coupled anti-E antibody 3H5.1, and subjected to flow-cytometric analysis. Mock-
infected cells and an IgG isotype control (murine IgG2a) antibody were used as controls. Titrations of the virus particles released at 43 hpi from
infected K562 cells (B), U937 cells (C), and primary human PBMCs (D) were performed by plaque assay on BHK-15 cells. Data are expressed as means
of at least three independent experiments. The error bars represent standard deviations (SD); (n.d.) denotes ‘‘not detectable’’.
doi:10.1371/journal.ppat.1000718.g001
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occur upon interaction of immature DENV particles with
antibodies, we incubated
35S-methionine-labeled immature parti-
cles in the absence and presence of antibodies with exogenous
furin for 16 h at pH 6.0 [16]. Protein visualization was done by
SDS-PAGE analysis. In agreement with previous studies, we
observed that exogenous furin treatment induces efficient cleavage
of prM to M (Fig. 3C). Importantly, we found that the presence of
prM antibodies does not affect DENV maturation, as virtually
complete cleavage of prM to M was observed (Fig. 3C).
Antibody-mediated entry of immature dengue virus
particles does not lead to an increased production of
virus particles per cell
It has been postulated that antibody-mediated entry of DENV
leads to a higher production of virus particles per infected cell, a
phenomenon often referred to as intrinsic ADE [30]. In this part of
the study, we investigated whether prM-mediated entry of immature
DENV supports intrinsic ADE. Since immature particles are
essentially non-infectious in the absence of antibodies, we compared
the production of prM-opsonized immature DENV particles with
wild-type virus in K562 cells. For accurate comparison, we first
searched for a condition that gives a similar percentage of infected
cells. Infection of K562 cells with prM-opsonized immature DENV
at a MOG of 100 leads to 0.53%+/20.14 infected cells (Fig. 1, 4A).
Comparable numbers of infected cells were detected for wild-type
DENV at MOG 10 (Fig. 4A). Under these experimental conditions,
no differences were observed inE protein expression and production
of virus particles (Fig. 4B–C), which indicates that the presence of
prM antibodies, while evidently stimulating the infectious properties
of immature virions, has no enhancing effect on the number of
progeny virions produced per cell.
Antibody against prM enhances the infectivity of
wild-type dengue virus in a furin-dependent manner
Given the high number of prM-containing particles in wild-type
DENV preparations it is possible that prM antibodies also enhance
the infectious properties of wild-type DENV. Indeed, in agreement
with previous studies, opsonization of wild-type virus with prM
antibodies results in a significant increase of viral infectivity
(Fig. 5A-C, Fig. S3) [24,25]. The level of enhancement is dependent
on the cell type used and comparable to what has been described
before for E antibodies [31,32]. Enhancement of wild-type DENV
infection was observed at higher antibody concentrations compared
to that of immature particles. Although we do not completely
understandthesedifferences,wethinkthatthismayberelated tothe
presence of structurally distinct immature virus particles (individual
variations in prM/M content) in wild-type preparations [17].
Importantly, no enhancement of infection was observed in cells
treated with furin inhibitor (Fig. 5D), demonstrating that furin
activity in the targetcells plays a vital roleintriggering the infectious
properties of antibody-opsonized immature particles in wild-type
DENV preparations. Collectively, these results illustrate that prM
antibodies enhance the infectious properties of prM-containing
particles in wild-type DENV preparations and therefore may be
important in disease pathogenesis.
Dengue-immune sera enhances the infectious properties
of immature dengue virus particles
As a first step towards elucidation of the implications of our
findings in disease pathogenesis we evaluated the enhancing
properties of 7 convalescent serum samples from patients infected
with DENV-2. The infectious properties of immature particles
opsonized with various dilutions of polyclonal sera were
determined in U937 cells, since this cell line expresses both Fc
receptors CD32 and CD64 on the cell surface. At 43 hr post-
infection, the medium was harvested and the production of virus
particles was measured by plaque assay. No plaques were found in
the absence of sera and in the presence of DENV-naı ¨ve serum
(Fig. 6). Convalescent sera from two distinct DENV-2 infected
patients significantly enhanced the infectious properties of
immature DENV particles at a 10,000 dilution (Fig. 6). Sera from
two other patients enhanced the infectivity of immature particles
to a minor extent as only a low number of plaques (average of 1.5
plaques) was observed. The three remaining patient sera did not
show any effect on viral infectivity of immature particles as no viral
Figure 2. Anti-prM antibody stimulates binding of immature DENV particles to cells through interaction with FccIIR. (A) Binding of
immature and wild-type virions with and without prior opsonization to antibodies (40 ng/ml) to K562 cells. Virus-cell binding was measured after 1 h
incubation at 4uC by q-PCR analysis. (B) Effect of anti-CD32 mAb and 70–21 F(ab’)2 fragments on virus particle production. Virus particle production
was determined as described in the legend to Figure 1B. Data are expressed as means and SD of three independent experiments. Two-tailed
Student’s t-tests were performed for statistical analysis of the data.
doi:10.1371/journal.ppat.1000718.g002
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patient sera enhanced the infectious properties of wild-type virus
particles (Fig. S4).
Discussion
Multiple studies have shown that immature particles are non-
infectious, the presence of prM obstructing the low-pH-induced
conformational changes in the viral E glycoprotein required for
membrane fusion of the virus [14,16,18,21,22,33]. On the other
hand, prM antibodies have been shown to enhance DENV infection
[24,25]. In this report, we show that the lack of infectivity of fully
immatureparticlesintheabsenceofantibodiesisprimarilyrelatedto
inefficient binding of immature virions to the cell surface. If binding
isfacilitatedthroughanti-prMantibodies,immatureDENVparticles
become highly infectious presumably due to efficient intracellular
processing of prM to M by the endoprotease furin.
Maturation upon entry has been previously reported for other
enveloped viruses. Zhang and co-workers [34] showed that the
infectivity of immature particles of Semliki Forest virus, an
alphavirus, can be triggered by furin during viral endocytosis. It is
likely that DENV maturation also occurs within acidic endosomes,
since previous in vitro experiments have revealed that cleavage of
immature particles by furin is dependent on the exposure of the
virus to low pH [16]. We propose that the acidic conditions of the
endosome, similar to those in the acidic TGN during processing of
newly assembled virions, triggers an initial conformational change
in the virion such that furin is able to cleave prM to M and the
‘‘pr’’ peptide. Interestingly, a recent report has shown that upon
cleavage of prM a large fraction of pr peptide remains associated
with the virion and that back-neutralization to pH 8.0 is required
to release the pr peptide from the virion [14]. The authors
interpreted this as a mechanism preventing newly assembled
cleaved virions from undergoing membrane fusion in the acidic
TGN. However, this notion is difficult to reconcile with our
present observations, since virions that have matured within acidic
endosomes of target cells do not return to neutral-pH conditions
before initiating infection. One may speculate that the pr peptide
Figure 3. Immature DENV particles mature upon FccIIR-mediated cell entry. (A) K562 cells were infected with DENV or DENV-immune
complexes in the presence or absence of furin inhibitor (25 mM). As a positive control for compound activity, wild-type DENV-infected cells were
treated with an additional dose of furin inhibitor at 24 hpi to impede virus maturation and consequently the production of infectious virions (++).
Virus particle production was determined as described in the legend to Figure 1B. Data are expressed as means and SD for three independent
experiments; (n.d.) denotes ‘‘not detectable’’. (B) K562 cells were infected with DENVprMD90 at MOG 100 in the presence of increasing
concentrations of prM antibody 70–21. As control, the infectivity of wild-type virus (generated from the infectious clone pD2/IC-30P) at MOG 100 is
shown. Virus production was assessed as described in the legend to Figure 1B. (C) prM antibodies do not affect cleavage maturation of DENV
particles. Purified [
35S]methionine-labeled immature particles with and without enhancing concentrations of anti prM mAb 70–21 were incubated
with furin at pH 6 for 16 h. Next, viral protein composition was analyzed by non-reducing SDS-polyacrylamide gel electrophoresis.
doi:10.1371/journal.ppat.1000718.g003
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acidic lumen of the TGN (,pH 6.0), but is released at the more
acidic pH of endosomes (,pH 5.0) such that the E proteins have
the capacity to rearrange to their fusion-active conformation.
Another possibility is that upon cleavage of prM the pr peptide
associates with the prM antibody instead of the E protein, thereby
enabling the E proteins to adopt the fusion-active conformation.
The observed infectious potential of immature DENV virions in
the presence of anti-prM antibodies may have important
implications for our understanding of the processes involved in
dengue pathogenesis. We speculate that in the early stages of a
primary infection, before the appearance of virus-specific anti-
bodies, immature virions would fail to penetrate host cells and
therefore are of minor significance in disease development. On the
other hand, during a secondary infection or primary infection of
infants born to dengue-immune mothers, immature particles may
become highly infectious due to the presence of anti-prM
antibodies and hence may contribute to an increased dengue-
infected cell mass and a high circulating virus titer, one of the
preludes for the development of severe disease symptoms [3,8–11].
Importantly, anti-prM antibodies may activate the infectious
properties of a large population of virus particles, since we recently
observed that a typical DENV-2 preparation of the prototype
strain 16681 contains as much as 30% prM [16]. Taken together,
our results suggest that immature DENV particles act as a veiled
pathogen and can, like mature DENV contribute to the disease
pathogenesis.
Variable levels of enhancement were seen with DENV-immune
sera. As expected, virtually all of analyzed DENV-immune sera
stimulated the infectivity of wild-type DENV. Interestingly, sera
from 2 out of 7 patients significantly enhanced the infectious
properties of immature particles. This suggests that individual
patients develop different responses to prM. On the basis of these
results, we believe that it is important to further investigate the
antibody responses in DENV-infected patients and to unravel if
patients with prM antibodies are more susceptible to develop severe
disease. In this respect, it is interesting to note that the rates of prM
antibody responses are significantly higher in patients experiencing
a secondaryinfectioncomparedtoaprimaryinfection[23].Clearly,
future clinical studies are required to obtain further evidence for
the role of immature particles and prM antibodies in disease
development.
Materials and Methods
Cells
Aedes albopictus C6/36 cells were maintained in minimal essential
medium (Life Technologies) supplemented with 10% fetal bovine
serum (FBS), 25 mM HEPES, 7.5% sodium bicarbonate, penicillin
(100 U/ml), streptomycin (100 mg/ml), 200 mM glutamine and
Figure 4. FcR-mediated entry of immature DENV does not enhance the number of progeny virions produced per cell. K562 cells were
infected with immature (prM) DENV-2 at MOG 100 in the absence or presence of 40 ng/ml of 70–21 antibody and with wild-type virus at MOG 10 and
100. (A) At 43 hpi, the cells were fixed, stained intracellularly with Alexa-647-coupled anti-E antibody 3H5.1, and subjected to flow-cytometric analysis.
Mock-infected cells and an irrelevant murine IgG2a antibody were used as controls. (B) Mean fluorescent intensity of cells infected with immature
virus (MOG 100) and wild-type DENV (MOG 10) (C) Titration of the virus particles released at 43 hpi from infected K562 cells using plaque assay. Data
are expressed as means of at least three independent experiments. The error bars represent standard deviations (SD).
doi:10.1371/journal.ppat.1000718.g004
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Hamster Kidney-21 clone 15 cells (BHK-15) cells were cultured
in DMEM (Life Technologies) containing 10% FBS, penicillin
(100 U/ml), streptomycin (100 mg/ml), 10 mM HEPES, and
200 mM glutamine. Human adenocarcinoma LoVo cells were
cultured in Ham’s medium (Life Technologies) supplemented with
20% FBS at 37uC, 5% CO2. Human erythroleukemic K562 cells
were maintained in DMEM supplemented with 10% FBS,
penicillin (100 U/ml), and streptomycin (100 mg/ml) at 37uC,
5% CO2. Human leukemic monocyte lymphoma U937 cells were
maintained in Iscove’s modified Dulbecco’s medium (GIBCO)
supplemented with 10% FBS, 4 mM L-glutamine, penicillin
(100 U/ml), and streptomycin (100 mg/ml) and adjusted to contain
1.5 g/l sodium bicarbonate, 10 mM HEPES and 1.0 mM sodium
pyruvate (GIBCO). Cells were incubated at 37uCa t5 %C O 2.
Human peripheral blood mononuclear cells (PBMCs) were
maintained in RPMI 1640 medium supplemented with 10%
FBS, penicillin (100 U/ml), and streptomycin (100 mg/ml).
PBMCs were isolated from heparinized blood samples collected
from healthy persons using standard density centrifugation
procedures with Lymphoprep
TM (AXIS-SHIELD). The PBMCs
were used immediately after isolation or cryopreserved at 2150uC.
On the day of infection, the percentage of CD14+, CD19-
population within isolated PBMCs was determined (5%–10%
depending on the blood donor) using cell surface markers CD-14
-FITC and CD19-R-PE purchased from commercial source (IQ
Products).
Figure 5. prM-specific antibody 70–21 enhances infectivity of wild-type DENV in a furin-dependent manner. Cells were infected with
wild-type (wt) DENV-2 at MOG 100 in the presence of increasing concentrations of anti-prM 70–21. Virus particle production was measured at 43 hpi
by plaque assay on BHK-15 cells. (A) K562 cells, (B) U937 cells, (C) PBMCs. (D) Enhancement of infection is dependent on endogenous furin activity.
K562 cells were infected with DENV with and without prior opsonization with 4000 ng/ml 70–21 in the presence or absence of furin inhibitor as
described in the legend to Figure 3. Data are expressed as means of at least three independent experiments. The error bars represent standard
deviations (SD); (n.d.) denotes ‘‘not detectable’’; * denotes significance (p,0.05) analyzed using Two-tailed Student’s t-tests.
doi:10.1371/journal.ppat.1000718.g005
Figure 6. Immature DENV becomes infectious in the presence of
DENV-immune sera. U937 cells were infected with immature (prM)
DENV-2 at MOG 100 in the presence of 10-fold sequential dilutions of
dengue patients sera. Virus particle production was measured at 43 hpi
by plaque assay on BHK-15 cells. Sera of two patients showed significant
enhancing activity towards immature DENV virions at a 10
4 sera dilution.
The error bars represent standard deviations (SD); (c.s.) denotes ‘‘control
serum’’; (n.d.) denotes ‘‘not detectable’’; * denotes significance (p,0.05)
analyzed using Two-tailed Student’s t-tests.
doi:10.1371/journal.ppat.1000718.g006
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DENV-2 strain 16681, kindly provided by dr. Claire Huang
(Center for Disease Control and Prevention, USA), was propa-
gated on C6/36 cells as described before [16]. Briefly, monolayer
of C6/36 cells was infected at multiplicity of infection (MOI of
0.1). At 96 hpi, the medium was harvested, cleared from cellular
debris by low-speed centrifugation, aliquoted, and stored at
280uC. Immature DENV particles were produced on LoVo cells
as described previously [16]. Briefly, LoVo cells were infected at
MOI 10. Virus inoculum was removed after 1.5 h and fresh
medium was added after washing the cells twice with PBS. At 72
hpi, the medium containing the virus particles was harvested,
cleared from cellular debris by low-speed centrifugation, aliquoted,
and stored at 280uC. [
35S] methionine-labeled immature virus
was prepared, as described previously [16]. Briefly, cells were
infected at a MOI of 10. At 2 hpi, 400 mCi of [
35S]methionine
(Amersham Biosciences) was added to 20 ml of medium and
incubation was continued overnight. At 23 hpi, the medium was
supplemented with an additional 200 mCi of radioactive label.
At 72 hpi, the supernatant containing the viral particles was
cleared from cell debris by low-speed centrifugation and the
virions were pelletted and further purified on a discontinuous
(20 and 55% w/v) Optiprep
TM gradient (Axis-Shield) by
ultracentrifugation. Virus was harvested from the gradient
interface, aliquoted and stored at 280uC. Virus preparations
were analyzed with respect to the infectious titer and the
number of genome-containing particles, as described previously
[15,16].
The furin-cleavage mutant (pDENprMD90) was generated by
deletion of the lysine codon within the furin-recognition site at
position 90 of prM. The mutation was introduced in the DENV-2
16681 infectious cDNA clone (pD2/IC-30P) [35]. Briefly, two
PCR fragments were generated using the following primers:
forward primer A (59-CTC AAC GAC AGG AGC ACG ATC
AT- 39) and reverse primer A (59- GAG TGC CAC TGA TCT
TTC TCT TC-39) and forward primer B (59- GAA GAG AAA D
GAT CAG TGG CAC TCG TT-39) and reverse B (59-GTG TCA
TTT CCG ACT GCA TGC TCT-39). The PCR fragments were
ligated, cut with SacI and Sph1, and ligated into pD2/IC-30P.
The introduced deletion was confirmed by DNA sequence analysis
using an automated capillary sequencing system (ABI). RNA
transcripts were generated from pDENprMD90 and pD2/IC-30P
using T7 RNA polymerase and transfected into BHK-15 cells
cells by electroporation (Bio-Rad Gene Pulser apparatus; two
pulses at 1.5 kV, 25 mF, and 200 V). At 12 hours post transfection
(hpt) cells were washed extensively to remove remaining RNA
copies. Virus preparations were harvested at 72 hpt, cleared
from cellular debris by low-speed centrifugation, aliquoted, and
stored at 280uC. Virus preparations were analyzed with respect
to the infectious titer and the number of genome-containing
particles, as described previously. The antigenic reactivity of
DENVprMD90 was compared to LoVo-derived virus by standard
three-layer ELISA. Briefly, microtiter ELISA plates (Greiner bio-
one) were coated with 4610
6 GCP of different virus preparations
per well in 100 ml coating buffer, overnight. After blocking
with 2% milk in coating buffer for 45 min, 100 ml of two-fold
serial dilutions of anti-DENV mAbs were applied to the wells
and incubated for 1.5 h, in triplicate. Subsequently, 100 mlo f
horseradish peroxidase-conjugated goat anti-mouse IgG-isotype
antibody (Southern Biotech) was applied for 1 h. All incuba-
tions were performed at 37uC. Staining was performed using
o-phenylene-diamine (OPD) (Eastman Kodak Company) and
absorbance was read at 492 nm (A492) with an ELISA reader (Bio-
tek Instruments, Inc.).
Patient sera
Convalescent sera from DENV-2 immune, hospitalized patients
were kindly provided by dr. G. Comach (Biomed-UC, Lardidev,
Maracay, Venezuela) and dr. T. Kochel (U.S. Naval Medical
ResearchCenterDetachment,Lima,Peru).Allserasamplesanalyzed
were obtained between 20–28 days following DENV-infection.
Infectivity assays
Virus or virus-antibody complexes were added to 2610
5 K562
cells, at a multiplicity of 100 genome-containing particles (MOG)
per cell. After 1.5 h incubation at 37uC, the inoculum was
removed and fresh medium was added to the cells. At 24–48 hpi,
the medium was harvested and virus production was analyzed by
plaque assay on BHK-15 cells, as described previously [36]. To
measure the number of infected cells, cells were fixed at 24–48 hpi,
stained with 3H5-conjugated Alexa647, and analyzed using a
FACS Calibur cytometer. For virus-antibody complex formation,
virus particles were incubated for 1 h at 37uC with various
dilutions of monoclonal prM antibody 70-21 and 2H2 in cell
culture medium containing 2% FBS prior to the addition to cells.
To investigate the involvement of the Fc receptor, mAb 70–21
F(ab’)2 fragments produced by use of the immobilized pepsin
(Pierce) were used. Alternatively, K562 cells were pretreated with
25 mg/ml of anti-FccRII antibody (MCA1075PE, Serotec) for 1 h
at 37uC, after which access antibody was removed by extensive
washing. In furin blockage experiments, cells were treated with
25 mM of furin-specific inhibitor, decanoyl-L-arginyl-L-valyl-L-
lysyl-L-arginyl-chloromethylketone (decRRVKR-CMK) (Calbio-
chem) prior and during virus infection. In control sample for the
decRRVKR-CMK activity, additional 25 mM of the inhibitor was
added to ensure blockage of the progeny virus maturation.
Binding assays
To determine the number of bound genome-containing
particles per cell, virus or virus-antibody complexes were
incubated with 2610
5 K526 cells at MOG 1000 for 1 h at 4uC.
Subsequently, cells were washed three times with ice-cold PBS
containing MgCl2 and CaCl2 (Life Technologies) to remove
unbound virus-antibody complexes. Then, viral RNA was
extracted from the cells by use of the QIAamp Viral RNA mini
Kit (QIAGEN). Thereafter, cDNA was synthesized from the viral
RNA with reverse transcription-PCR (RT-PCR), copies of which
were quantified using quantitative PCR [15].
In vitro furin cleavage assays
[
35S]methionine-labeled immature particles or viral immune
complexes were incubated with furin [New England BioLabs] for
16 h at pH 6.0, as described previously [16]. Following furin
treatment samples were subjected to sodium dodecyl sulphate-
polycrylamide gel electrophoresis (SDS-PAGE) analysis to visual-
ize the protein composition.
Supporting Information
Figure S1 Time course of the number of DENV-infected K562
cells. Cells were infected with wild-type DENV at MOG 100. At
the indicated time points, cells were fixed, stained intracellularly
with Alexa-647-coupled anti-E antibody 3H5.1, and subjected to
flow-cytometric analysis. MFI denotes ‘‘mean fluorescence inten-
sity’’ of infected cells.
Found at: doi:10.1371/journal.ppat.1000718.s001 (0.01 MB PDF)
Figure S2 prM antibody 2H2 enhances the infectious properties
of immature DENV particles. Cells were infected with immature
prM Antibodies Render Immature DENV Infectious
PLoS Pathogens | www.plospathogens.org 8 January 2010 | Volume 6 | Issue 1 | e1000718(prM) or wild-type (wt) DENV-2 particles at MOG 100 in the
presence or absence of anti-prM 2H2. Virus particle production
was measured at 43 hpi by plaque assay on BHK-15 cells. (A)
K562 cells, (B) U937 cells, (C) PBMCs. Data are expressed as
means of at least two independent experiments. The error bars
represent standard deviations (SD); (n.d.) denotes ‘‘not detectable’’.
Found at: doi:10.1371/journal.ppat.1000718.s002 (0.01 MB PDF)
Figure S3 prM antibody 2H2 enhances the infectious properties
of wild-type DENV in various cell types. Cells were infected with
wild-type (wt) DENV-2 at MOG 100 in the presence of increasing
concentrations of 2H2. Virus particle production was measured at
43 hpi by plaque assay on BHK-15 cells. (A) K562 cells, (B) U937
cells, (C) PBMCs. Data are expressed as means of at least three
independent experiments. The error bars represent standard
deviations (SD); (n.d.) denotes ‘‘not detectable’’; * denotes
significance (p,0.05) analyzed using Two-tailed Student’s t-tests.
Found at: doi:10.1371/journal.ppat.1000718.s003 (0.01 MB PDF)
Figure S4 DENV-immune sera stimulate infectivity of wild-type
DENV. U937 cells were infected with wild-type (wt) DENV at
MOG 100 in the presence of 10-fold sequential dilutions of
polyclonal sera. Virus particle production was measured at 43 hpi
by plaque assay on BHK-15 cells. Viral titers obtained at 10
4 sera
dilution are depicted on the plot. The error bars represent
standard deviations (SD).
Found at: doi:10.1371/journal.ppat.1000718.s004 (0.01 MB PDF)
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